Amgen Inc. $AMGN Position Cut by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 15.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,809 shares of the medical research company’s stock after selling 8,585 shares during the quarter. Caisse de depot et placement du Quebec’s holdings in Amgen were worth $17,313,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Man Group plc increased its holdings in shares of Amgen by 64.2% in the 2nd quarter. Man Group plc now owns 234,023 shares of the medical research company’s stock worth $84,744,000 after acquiring an additional 91,498 shares during the period. Western Wealth Management LLC boosted its stake in Amgen by 0.8% during the 2nd quarter. Western Wealth Management LLC now owns 10,288 shares of the medical research company’s stock valued at $3,726,000 after purchasing an additional 81 shares during the period. Councilmark Asset Management LLC boosted its stake in Amgen by 0.3% during the 2nd quarter. Councilmark Asset Management LLC now owns 10,011 shares of the medical research company’s stock valued at $3,625,000 after purchasing an additional 30 shares during the period. Polar Asset Management Partners Inc. bought a new position in Amgen in the 2nd quarter worth about $201,000. Finally, Jupiter Topco LLC bought a new position in Amgen in the 2nd quarter worth about $323,681,000. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire expands its potential market. Amgen and AstraZeneca reported that Tezspire met both co-primary and all key secondary endpoints in the Phase 3 CROSSING study for eosinophilic esophagitis (EoE). Improvements in tissue inflammation and swallowing symptoms were statistically significant, clinically meaningful and sustained through 52 weeks. EoE could become Tezspire’s third approved indication, adding a potentially significant growth opportunity beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 EoE Results
• Positive Sentiment: Recent financial performance remains supportive. Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Strong results and full-year guidance have helped keep the stock near its 52-week high and provide a favorable backdrop for pipeline news. Amgen Earnings and Guidance
• Neutral Sentiment: Additional pipeline updates offer limited near-term valuation impact. Amgen provided updates on a pediatric psoriasis study involving apremilast and began a Phase 1 trial of AMG 691 aimed at markets in Asia. These programs may support long-term growth, but both remain too early to materially affect current earnings expectations. Amgen Pediatric Psoriasis Study
• Negative Sentiment: Amgen ended its Crohn’s disease research partnership with TScan Therapeutics. Terminating the collaboration removes an external source of potential inflammatory bowel disease assets and may raise questions about the company’s strategy in this research area. The impact is likely limited near term because the program was still focused on target discovery. Amgen Ends Crohn’s Research Partnership

Analyst Ratings Changes

A number of research firms have recently weighed in on AMGN. Mizuho lifted their price target on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Morgan Stanley reaffirmed an “overweight” rating and set a $362.00 target price on shares of Amgen in a research note on Wednesday, August 19th. Robert W. Baird increased their price target on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Weiss Ratings raised Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Finally, Truist Financial lifted their price objective on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $380.43.

Amgen Stock Performance

AMGN opened at $432.42 on Friday. The business has a 50 day moving average price of $388.64 and a two-hundred day moving average price of $364.71. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $233.78 billion, a price-to-earnings ratio of 26.88, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the firm earned $6.02 EPS. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts predict that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Insider Activity

In other news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.